JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Results of Operations and Financial Condition
Item2.02.
| Results of Operation and Financial Condition |
On March7, 2017, Juniper Pharmaceuticals, Inc. (the Company),
issued a press release announcing the financial results for the
three-month and twelve-month periods ended December31, 2016,
entitled Juniper Pharmaceuticals Reports Fourth Quarter and
Full-Year 2016 Financial and Operating Results (the Press
Release). A copy of the Press Release is furnished as Exhibit
99.1 hereto and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section18 of the United State Securities Exchange Act
of 1934, as amended, or otherwise subject to the liability of
Section18. Furthermore, the information shall not be deemed
incorporated by reference into any registration statement or any
other filing under the United States Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
references in such filings.
| Item9.01. | Financial Statements and Exhibits |
(d)Exhibits
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release dated March7, 2017, entitled Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results, furnished herewith |
About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)
Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301. JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Recent Trading Information
JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) closed its last trading session down -0.10 at 5.05 with 54,705 shares trading hands.
